Product Description
Mechanisms of Action: PDK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Colombia | India | Peru | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Saol Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Insulin Resistance
Phase 3: Acidosis, Lactic|Pyruvate Dehydrogenase Complex Deficiency Disease
Phase 2: Head and Neck Cancer|MELAS Syndrome|Breast Cancer|Healthy Volunteers|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Multiple Myeloma|Glioblastoma|Glioma|Acidosis, Lactic
Phase 1: Glioblastoma|Tumor Lysis Syndrome|Potassium Deficiency|Protein Deficiency|Lung Cancer|Brain Death|Liver Cancer|Acidosis, Lactic|Breast Cancer|Evans Syndrome|Brain Cancer|MELAS Syndrome|Pyruvate Dehydrogenase Complex Deficiency Disease|Deficiency Diseases|Hypoglycemia|Type 1 Diabetes|Healthy Volunteers|Mitochondrial Diseases|Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Head and Neck Cancer|Hyperglycemia|Brain Injuries
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06656780 |
HSC-MS-24-0756 | N/A |
Not yet recruiting |
Generalized anxiety disorder |
2027-06-30 |
2024-10-25 |
||
ACTRN12623001164684 |
ACTRN12623001164684 | N/A |
Recruiting |
Nose Cancer |
2026-10-30 |
2025-04-28 |
Treatments |
|
ChiCTR2300074110 |
Application of a new portable ultrasonic diagnostic instrument | N/A |
Recruiting |
Other |
2025-07-31 |
2023-11-12 |
Treatments |
|
NCT06170515 |
NC002 | N/A |
Recruiting |
General Diabetes |
2024-03-31 |
2023-12-15 |
||
NCT04046081 |
EPiC | N/A |
Completed |
Endometriosis |
2021-09-30 |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04899362 |
SRIC-CA | N/A |
Completed |
Brain Ischemia |
2021-07-19 |
2021-10-15 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
ACTRN12617000555358 |
ACTRN12617000555358 | N/A |
Terminated |
Type 2 Diabetes|Type 1 Diabetes|Hypoglycemia |
2017-07-31 |
2024-08-29 |
Treatments |
|
NCT02965547 |
RIPCA | N/A |
Completed |
Brain Ischemia |
2017-05-01 |
2021-08-25 |
Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT00874276 |
14617-CP-004 | N/A |
Completed |
Acidosis, Lactic |
2012-11-01 |
2019-03-18 |
Treatments |
|
NCT01333176 |
H10-02551 | N/A |
Unknown status |
Type 2 Diabetes |
2012-06-01 |
2019-03-19 |
Treatments |
|
NCT00865514 |
14617-CP-001 | N/A |
Terminated |
Healthy Volunteers |
2012-01-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT05317455 |
NCT05317455 | P1 |
Recruiting |
Type 1 Diabetes|Hypoglycemia |
2026-05-01 |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT03356457 |
NCT03356457 | P1 |
Completed |
Hypoglycemia|Hyperglycemia|Brain Injuries |
2019-03-20 |
2021-01-25 |
||
NCT02690285 |
IRB201500995 - N | P1 |
Completed |
Pyruvate Dehydrogenase Complex Deficiency Disease|Mitochondrial Diseases|Deficiency Diseases |
2017-05-30 |
2019-03-20 |
Treatments |
|
NCT01163487 |
IRB-18245 | P1 |
Completed |
Head and Neck Cancer |
2015-02-01 |
2019-03-19 |
Treatments |
|
NCT01111097 |
CTSI | P1 |
Completed |
Brain Cancer|Glioblastoma |
2014-03-01 |
2019-03-19 |
Treatments |
|
NCT01083524 |
DCA 20001 | P1 |
Completed |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2013-09-01 |
2019-03-19 |
Treatments |
|
NCT01807702 |
PBT | P1 |
Completed |
Healthy Volunteers |
2013-07-01 |
2019-03-19 |
Treatments |
|
NCT00566410 |
DCA | P1 |
Completed |
Protein Deficiency|Lung Cancer|Brain Death|MELAS Syndrome|Evans Syndrome|Brain Cancer|Breast Cancer|Acidosis, Lactic|Liver Cancer|Potassium Deficiency|Tumor Lysis Syndrome |
2013-03-01 |
2019-03-22 |
Treatments |
|
NCT05173623 |
DCA | P2 |
Not yet recruiting |
Glioblastoma |
2026-12-30 |
2021-12-31 |
Primary Endpoints|Treatments |
|
NCT05120284 |
IRB202101509 | P2 |
Active, not recruiting |
Glioblastoma |
2026-07-01 |
2025-08-30 |
Primary Endpoints|Treatments|Trial Status |
|
NCT01386632 |
DCA 2010 | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2014-08-01 |
2020-10-28 |
||
NCT01128270 |
IRB#107-10 | P2 |
Completed |
Healthy Volunteers |
2012-10-01 |
2019-03-19 |
||
NCT02616484 |
DCA/PDCD | P3 |
Active, not recruiting |
Pyruvate Dehydrogenase Complex Deficiency Disease |
2025-08-27 |
4% |
2025-05-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT02469337 |
CARBEX | P4 |
Unknown status |
Insulin Resistance |
2017-06-01 |
2019-03-20 |
Treatments |